Uromigos Live 2024 ADCs in UC Panel Part 4: Novel ADCs Including HER3 and Novel Nectin-4

At Uromigos Live 2024, a bladder cancer panel moderated by Dr. Tom Powles focused on the use of antibody drug conjugates for the treatment of bladder cancer, analyzing the response rates of various ADC treatments and their related side effects.

Dr. Powles was joined by Andrea Apolo, MD, of the National Institute of Health; Petros Grivas, MD, PhD, of the University of Washington; Shilpa Gupta, MD, of Cleveland Clinic; and Kala Sridhar, MD, of Princess Margaret Cancer Center.

During the fourth segment of this panel, novel ADCs including HER3, Nectin-4, and BT8009 are analyzed.

Watch the final part of this panel: How to Design Future Trials With Novel ADCs to Change Practice